NAVB vs. IDXX, LNTH, QDEL, NEOG, CLDX, NTLA, MYGN, ACHV, TKNO, and VNRX
Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include IDEXX Laboratories (IDXX), Lantheus (LNTH), QuidelOrtho (QDEL), Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Achieve Life Sciences (ACHV), Alpha Teknova (TKNO), and VolitionRx (VNRX). These companies are all part of the "diagnostic substances" industry.
Navidea Biopharmaceuticals (NYSE:NAVB) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.
IDEXX Laboratories has a consensus target price of $580.38, suggesting a potential upside of 16.79%.
Navidea Biopharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
IDEXX Laboratories has a net margin of 23.26% compared to Navidea Biopharmaceuticals' net margin of 0.00%. IDEXX Laboratories' return on equity of 63.66% beat Navidea Biopharmaceuticals' return on equity.
0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 2.1% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
IDEXX Laboratories received 527 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 72.69% of users gave IDEXX Laboratories an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote.
IDEXX Laboratories has higher revenue and earnings than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
In the previous week, IDEXX Laboratories had 7 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 8 mentions for IDEXX Laboratories and 1 mentions for Navidea Biopharmaceuticals. IDEXX Laboratories' average media sentiment score of 1.55 beat Navidea Biopharmaceuticals' score of 0.00 indicating that IDEXX Laboratories is being referred to more favorably in the news media.
Summary
IDEXX Laboratories beats Navidea Biopharmaceuticals on 13 of the 14 factors compared between the two stocks.
Get Navidea Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Navidea Biopharmaceuticals Competitors List
Related Companies and Tools
